Last reviewed: May 17, 2026
Last updated: May 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Midi Health and Ro both operate as telehealth platforms offering GLP-1 access, yet their clinical models, cost structures, and patient support mechanisms differ meaningfully. Each platform approaches medication selection, provider consultation, and ongoing monitoring in distinct ways that merit careful evaluation.
Choosing between telehealth providers requires understanding not just price, but how each platform's clinical framework aligns with your personalized needs. This guide helps you assess both platforms through a clinical lens, supported by evidence-based decision-making with your healthcare provider.
Clinical Models: How Provider Oversight and Monitoring Differ
Midi Health emphasizes ongoing provider relationships, with board-certified physicians conducting initial consultations and regular follow-ups. Their model prioritizes medication titration adjustments based on patient feedback and clinical response, with emphasis on behavioral support alongside pharmacotherapy.
Ro uses a simplified initial consultation model with qualified prescribers, focusing on rapid access and self-directed adjustments within safety parameters. This approach suits patients seeking quick onboarding but may offer less granular clinical guidance during titration or when switching medications.
Cost, Dosing Flexibility, and Access Architecture
Pricing structures between these platforms reveal different value propositions. Ro typically charges subscription-based monthly fees plus medication costs, while Midi Health integrates provider fees into bundled pricing. Dosing availability and medication options also vary: Ro offers branded and some compounded GLP-1 options, whereas Midi Health restricts to specific formulations.
Access speed differs notably. Ro can initiate treatment within days, leveraging automated workflows. Midi Health requires more thorough initial evaluation, adding 1-2 weeks but potentially yielding better baseline clinical clarity and personalization potential before starting medication.
| Comparison Factor |
Midi Health |
Ro |
| Consultation Type |
Extended provider-led evaluation with behavioral focus |
Brief automated or brief provider assessment |
| Follow-up Schedule |
Regular check-ins with titration adjustments |
Patient-initiated, optional follow-ups |
| Medication Options |
Limited formulary, compounded availability varies |
Broader branded and compounded access |
| Startup Timeline |
1–2 weeks with thorough initial workup |
2–5 days with streamlined intake |
Medication Selection and Personalization Frameworks
Midi Health's platform often includes behavioral assessment and lifestyle inventory before medication selection, attempting to match GLP-1 choice to behavioral readiness and comorbidity profile. This approach may reduce side effect burden for some patients by optimizing initial dosing and drug choice upfront.
Ro offers broader medication variety, allowing patients to switch between semaglutide, tirzepatide, and other GLP-1 options more easily within the same platform. However, this flexibility assumes patient knowledge of medication differences and may require self-directed decision-making without genetic or biomarker context.
Safety, Monitoring, and Who Qualifies for Each Platform
Both platforms screen for contraindications including personal/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and uncontrolled hypertension. Midi Health's extended evaluation may catch more complex drug interactions or behavioral barriers early. Ro's rapid access suits lower-risk candidates but requires greater self-awareness of side effect management.
Eligibility differs slightly: Midi Health may decline patients requiring intensive behavioral intervention alongside medication; Ro accepts broader candidate ranges but leaves monitoring responsibility to patients. Neither platform currently incorporates genetic testing into standard treatment selection, limiting precision personalization available through specialized compounding providers.
How PlexusDx Supports a More Personalized Approach
PlexusDx takes a precision-wellness approach by integrating genetic insights into GLP-1 pathway predispositions alongside compounded medications from licensed 503A pharmacies. Our Precision Peptide Genetic Test may help provide context about your individual genetic variations in GLP1R, GIPR, MC4R, and FTO pathways—factors that may influence medication response and side effect risk.
The genetic test reveals predispositions in peptide metabolism pathways, not exact medication responses. This information should be interpreted with a qualified healthcare provider to inform whether compounded semaglutide, tirzepatide, or dual-compound approaches may align better with your genetic profile. Genetic insights support more informed conversations without replacing clinical judgment.
Unlike telehealth platforms that rely on symptom reporting alone, PlexusDx connects genetic predisposition data with compounded medication options and provider guidance, enabling more tailored treatment planning. This framework may reduce trial-and-error medication selection, especially for patients with complex metabolic profiles or prior medication sensitivities.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What's the main difference in provider involvement between Midi Health and Ro?
Midi Health emphasizes ongoing provider relationships with regular consultations and behavioral support, while Ro uses streamlined initial assessments and optional follow-ups. Midi Health may offer more personalized titration; Ro prioritizes speed and patient autonomy.
How do costs compare between Midi Health and Ro over 6 months?
Ro's monthly subscription plus medication ranges $100–300/month depending on dosing; Midi Health bundles provider fees with medication, typically $129-$369/mo. Total costs depend on your starting dose, state regulations, and any required follow-ups.
Which platform is better for patients with complex medical histories?
Midi Health's extended evaluation may suit complex cases better, as their providers review interactions and comorbidities thoroughly. Ro works well for low-risk, straightforward candidates. Both require honest disclosure of medical history at intake.
Can I switch medications easily on either platform?
Ro permits easier medication switching within their formulary; Midi Health may require additional provider consultation before changing drugs. Neither uses genetic testing to inform initial medication selection currently.
How does PlexusDx compare to Midi Health or Ro for personalized GLP-1 treatment?
PlexusDx offers compounded medications from licensed 503A pharmacies paired with optional Precision Peptide Genetic Testing, revealing predispositions in GLP1R, GIPR, and MC4R pathways. This supports more informed provider conversations about medication fit. Compounded options range $129-$369/mo, depending on formulation.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Weightwatchers Cost: Why Biomarkers Matter for Your Weight-Loss Strategy
PlushCare Cost Guide: Tiers, Eligibility Discounts, and What Affects